Klebsiella pneumoniae is an encapsulated, Gram-negative non-motile bacterium of the enterobacterales
family which typically colonizes the oropharynx and gastrointestinal (GI) tract. The classical form of Kp is mainly a
opportunistic nosocomial/ICU pathogen which causes infections in immunocompromised or at risk individuals with comorbidities.
Common Kp-related infections include pneumonia, urinary tract infection (UTI), pneumonia, intraabdominal infection, bloodstream infection (BSI) and meningitis.
A hypervirulent form (hvKp) is capable of causing community-acquired infections, often in healthy individuals, with significant morbidity and mortality.
In the developing world, Kp is major cause of neonatal sepsis being responsible for 124,000 deaths [89,000-167,000] in 2019 (GBD 2019).
Worldwide (all syndromes) Kp caused 790,000 deaths [571-1,060,000] in 2019 being the 4th leading bacterial cause. Kp exhibit a high degree of antimicrobial resistance.
Carbapenem (CRE) and ESBL-producing Kp are considered a critical threat by the World Health Organisation (WHO).
A prophylactic Klebsiella pneumoniae vaccine could prevent invasive disease in a number of target populations both in Western developed countries and the developing world e.g., GAVI-assisted countries.
Several approaches are ongoing in both preclinical and clinical development with the most advanced being the GSK/LimmaTECH Bio Kleb4V (GSK4429016A),
a subunit conjugate approach which recently completed a Phase 1/2 study [NCT04959344].
Other earlier potential approaches are being pursued by GSK/Affinivax, Syntiron, Vaxdyn and Omniose.
This MarketVIEW product is a comprehensive Executive Presentation (>225 slides, .pdf) and interactive MS-Excel forecast model (120 worksheets, .xls)
which investigate the scenario-based uptake and commercial potential of Klebsiella pneumoniae vaccines across key target groups in 118 nations (public/private)
worldwide including HI income and GAVI/developing world countries. A thorough review of latest disease background/epidemiology/resistance trends data is presented along with discussion
of latest understanding of vaccinology/R&D competitor landscape. The analysis contains an in-depth commercial assessment of potential Klebsiella
pneumoniae vaccine profiles with discussion around target population rationale, potential uptake, pricing and clinical development feasibility/issues
THIS PRODUCT IS A SUMMARY PRESENTATION (~225 slides, .pdf) + 1 scenario-based interactive MS Excel Workbook(s)
Photo credit(s): Zach-vessels (@unsplash license)
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.